FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula (II) or its pharmaceutically acceptable salt, where R1 is where each R20 is independently selected from a group consisting of C1-6 alkyl, halogen, cyclopropyl, and C1-6 halogenalkyl, and p is 1, 2, or 3; Y1 is absent; Y2 is C(H)(R8); Y3 is CH; Z1 is N; Z2 is C(-L-R10a); Z3 is N; each of R4 and R5 is hydrogen; R8 is selected from a group consisting of H and C1-6 alkyl; -L-R10a is selected from a group consisting of
each of R13, R14, and R15 is H, or R13 is F, and each of R14 and R15 is H; X is substituted or unsubstituted piperazine, where the specified substituted piperazine is substituted with one group selected from a group consisting of CH3 and CH2CN; n is 0, and
is a single bond or a double bond. The invention also relates to a drug for the treatment of cancer mediated by mutation of protein K-Ras G12C.
EFFECT: new compounds are obtained, which can be used in medicine for the treatment of cancer diseases.
51 cl, 3 tbl, 62 ex
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
BICYCLOSUBSTITUTED AZOPYRAZOLONE DERIVATIVES SALTS, METHOD FOR PREPARING AND USING THEM | 2010 |
|
RU2538977C2 |
ARGINASE INHIBITORS AND THERAPEUTIC USE THEREOF | 2011 |
|
RU2586219C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
CETP INHIBITORS | 2006 |
|
RU2513107C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
AVB6 INTEGRIN INHIBITORS | 2018 |
|
RU2769702C2 |
PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
DERIVATIVES OF PYRIDINE AND APPLICATION THEREOF AGAINST MICROBACTERIA | 2015 |
|
RU2664587C1 |
Authors
Dates
2022-11-14—Published
2019-08-15—Filed